Iran, Cuba’s COVID-19 vaccine project proceeds to clinical trial phase II
A coronavirus vaccine project being jointly pursued by Iran and Cuba has entered phase II of its clinical trials, with no side effects having been reported so far.
Cuba and Iran signed an agreement earlier this month to cooperate in the coronavirus vaccine project with the use of a technology that will be transferred to Iran by Havana.
The vaccine, known as Subrana 2, is now undergoing its human phase trials by the Cuban Finlay Institute and the Pasteur Institute of Iran.
The vaccine, which is the most advanced one among Cuba’s four other coronavirus vaccines, has so far shown no side effects, as the initial stages of its testing have been completed successfully.
Iran also launched human trials of its first domestic coronavirus vaccine late last month.
The vaccine, known as COViran Barekat, is being produced under the health protocols and guidelines announced by the Ministry of Health and Medical Education.
Mohammad Mokhber, the director of the Headquarters for Executing the Order of Imam Khomeini, which is developing the vaccine, said on Monday that the third stage of the trials would see the injection of the vaccine to 56 volunteers.
The homegrown vaccine, Mokhber said, has been tested on volunteers in previous stages successfully without causing any side effects.
“We are trying to increase the production volume of the vaccine to up to three million doses per month in the next month,” he said.
Iran will reach the production of 14 million doses of the vaccine within the next four months with the continuation of this trend, according to Mokhber.
This comes as Iran is under illegal sanctions imposed by the United States, which have hampered its access to medical equipment and pharmaceuticals and have complicated the process of importing vaccines from other countries.